Harvard Bioscience appoints Stephen DeNelsky to board, effective Sept 5, 2025

HARVARD BIOSCIENCE INC

Stephen DeNelsky, Managing Director at Oaktree Capital Management, appointed to Board and Nominating & Governance Committee.
He has 30 years of healthcare equity research/valuation experience across life sciences, pharma, devices.
Compensation includes 110,000 RSUs and $91,000 annual cash retainer (total ~$135,000) for non-employee director.
DeNelsky also serves on board of Visioncare Inc and previously on Integrated Diagnostics and AMICAS.
No arrangement for his selection as director and no family relationships with other directors/officers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.